Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis

Akçalı, Cenk; Buyukcelik, Burcin; Kirtak, Necmettin; Inaloz, Serhat

doi:10.1177/0300060513502891

Cited by 28 publications

(33 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of the 35 articles, ten provided adjusted odds ratios after multivariate adjustment for factors such as age, sex, smoking, alcohol consumption, physical activity, and education [31, 34–42]. Among the remaining articles, 16 provided unadjusted odds ratios [30, 43–58], seven provided percent values for metabolic syndrome prevalence [59–65], and two provided specific numbers of patients affected without percent values or odds ratios. For the nine articles that did not provide any odds ratios, we calculated unadjusted odds that were then included in the meta-analysis (Table 1).…”

Section: Resultsmentioning

confidence: 99%

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

2017

View full text Add to dashboard Cite

The relationship between psoriasis and metabolic syndrome is not well understood. Though multiple epidemiologic studies have suggested a link between psoriasis and metabolic syndrome, there is a lack of a comprehensive meta-analysis synthesizing the results of all available observational studies to date. In this meta-analysis, we examined global data on the relationship between psoriasis and odds of metabolic syndrome by searching for studies published between 1946–2016. Specifically, we analyzed the results from 35 observational studies from 20 countries with 1,450,188 total participants, of which 46,714 were psoriasis patients. The pooled odds ratio based on random effects analysis was 2.14 (95% CI 1.84–2.48). Publication bias was present, as evidenced by an Egger test and graphical visualization through a funnel plot (p = 0.001). Based on this comprehensive meta-analysis, psoriasis patients have higher odds of having metabolic syndrome when compared with the general population.

show abstract

Section: Resultsmentioning

confidence: 99%

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

2017

View full text Add to dashboard Cite

show abstract

“…Bizim sonuçlarımız diğer ça-lışmaların sonuçları ile benzerlik göstermektedir. Son yıllarda çeşitli yayınlarda psoriazis hastalarında, santral obezite, tip 2 diyabet, insülin rezistansı, hipertansiyon ve kombine hiperlipidemiyi içeren metabolik sendrom riskinde artış olduğu gösterilmiştir [16]. Bizim çalışmamızda %18.6 olguda eş-lik eden sistemik hastalık mevcuttu.…”

Section: Discussionunclassified

Clinical and Demographic Characteristics of 626 Patients with Moderate and Severe Psoriasis

Rifaioğlu¹,

Özarmağan²

2014

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Çalışmamızda İstanbul Üniversitesi İstanbul Tıp Fakültesi Dermatoloji Anabilim Dalı psoriazis polikliniğinde takip edilen orta ve şiddetli psoriazis hastalarının demografik özelliklerini, klinik tiplerini ve kullanılan tedavileri incelemeyi amaçladık. Gereç ve Yöntem: Psoriazis polikliniğinde 2002-2008 yıl-ları arasında izlenen 1831 hasta tarandı, ve içlerinden orta ve şiddetli 626 (%34) olgu retrospektif olarak değerlendirildi. Bulgular: Çalışmamıza katı-lan olguların 305'i (%48.7) kadın, 321'i (%51.3) erkek olarak bulundu. Hastalık başlangıç yaşı 28.1 yıl ve en sık görülen klinik tip plak psoriazis olarak saptandı. Tırnak tutulumu saptanan hastalarda en sık pitting gözlendi. Artriti olan hastalarda tırnak tutulumu görülme sıklığı anlamlı şekilde yüksek bulundu. Ailede psoriazis bulunma öyküsü erken başlangıçlı psoriazis olguların-da daha sık saptandı. Sistemik tedaviler arasında en sık retinoik asit, fototerapi türleri arasında en sık dar bant UVB tedavisi kullanıldığı belirlendi. Tartışma: Orta ve şiddetli psoriazis oranı %34 olarak bulundu. Kadın erkek oranı arasında fark saptanmadı. Başlangıç yaşı 16-25 yaş arası pik yapıyordu. En sık eşlik eden sistemik hastalık diyabetes mellitus olarak bulundu. Çalışmamı-zın bulguları literatür ile uyumlu olarak belirlendi. Sonuç olarak psoriazis toplumun yaklaşık %2'sini etkileyen, komorbiditeleri ile hastaların yaşam kalitesini olumsuz yönde etkileyen, kronik, rekürren inflamatuar bir hastalıktır. Özel-likle şiddetli formları, hastalarda ciddi iş gücü kayıplarına neden olabilmektedir. Çalışmamızın psoriazisin demografik ve klinik özelliklerinin daha iyi anlaşılmasına yardım edecek ileri klinik çalışmalara ışık tutacağına inanıyoruz. Anahtar KelimelerPsoriazis; Sosyodemografi; Klinik Özellikler Abstract Aim: In our study, we aim to investigate the demographic, clinic features and the treatments of patients with moderate to severe psoriasis who were followed in outpatient clinic of psoriasis of Department of Dermatology in Istanbul Medical School of Istanbul University. Material and Method: One thousand eight hundred and thirty-one patients, who were followed between 2002-2008 in outpatient clinic of psoriasis, were screened and 626 (34%) of them, who were moderate and severe, were evaluated retrospectively. Results: Three hundred five of the patients who participated in our study were female and 321 were male. Mean age of onset was 28.1. Most frequently clinical type was plaque psoriasis. Most frequently nail involvement was pitting in patients. Nail involvement was statistically common in arthropathic patients. Family history was statistically common in psoriasis patients with early onset. Retinoid was the most common used systemic drug. Narrow band UVB was the most common used phototherapy. Discussion: Moderate to severe psoriasis rate was 34%. Female to male ratio was close to one another. Peak age of onset of psoriasis was between 16-25 years old. The most common concomitant systemic disease was diabetes mellitus. The findings were consistent with the lite...

show abstract

“…[14][15][16][17][18][19][20][21][22][23][24][25][26] Adiponectin has been negatively correlated with PASI (r = À0.34, P < 0.05) 17,19 and TNF-a levels (r = À0.64, P < 0.01). [14][15][16][17][18][19][20][21][22][23][24][25][26] Adiponectin has been negatively correlated with PASI (r = À0.34, P < 0.05) 17,19 and TNF-a levels (r = À0.64, P < 0.01).…”

Section: Obesity Weight Loss and Psoriasismentioning

confidence: 98%

Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction

et al. 2017

View full text Add to dashboard Cite

Adipokines are secreted by white adipose tissue, an active endocrine organ, and play a role in the regulation of metabolic functions such as lipid metabolism, inflammation, and vascular homeostasis. Adipokines are secreted in excess in obesity and contribute to the development of associated comorbidities such as metabolic syndrome and atherosclerosis. Psoriasis, a chronic immune-mediated skin disease, is associated with obesity and increased cardiovascular risk. Understanding the role of adipokines in psoriasis may in part explain the association between psoriasis and cardiovascular disease. This review summarizes the data regarding key adipokines in patients with psoriasis and the change in adipokine profiles with psoriasis therapy. Adipokines may be mediators of cutaneous inflammation suggesting a role in the pathophysiology of psoriasis and the development of comorbidities.

show abstract

Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis

Abstract: In this small study, metabolic syndrome was found to be more frequently identified in Turkish patients with psoriasis than in controls; metabolic syndrome could lead to increased cardiovascular disease risk in patients with moderate to severe psoriasis.

Cited by 28 publications

References 29 publications

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

Clinical and Demographic Characteristics of 626 Patients with Moderate and Severe Psoriasis

Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction

Contact Info

Product

Resources

About